MARKET

LTRN

LTRN

Lantern Pharma Inc
NASDAQ
4.060
-0.050
-1.22%
After Hours: 4.260 +0.2 +4.93% 17:07 05/14 EDT
OPEN
4.360
PREV CLOSE
4.110
HIGH
4.461
LOW
4.059
VOLUME
32.26K
TURNOVER
--
52 WEEK HIGH
6.80
52 WEEK LOW
2.550
MARKET CAP
43.79M
P/E (TTM)
-2.1026
1D
5D
1M
3M
1Y
5Y
1D
Lantern Pharma's Earnings Outlook
Benzinga · 1h ago
Lantern Pharma Inc <LTRN.OQ> expected to post a loss of 49 cents a share - Earnings Preview
Reuters · 1d ago
Lantern Pharma secures FDA clearance for planned Phase 1b/2 trial of LP-184
TipRanks · 2d ago
LANTERN PHARMA SECURES FDA CLEARANCE FOR PLANNED PHASE 1B/2 TRIAL OF LP-184 IN BIOMARKER-DEFINED, TREATMENT-RESISTANT NSCLC PATIENTS WITH HIGH UNMET CLINICAL NEED
Reuters · 2d ago
EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients
Benzinga · 2d ago
Weekly Report: what happened at LTRN last week (0505-0509)?
Weekly Report · 2d ago
Press Release: Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET
Dow Jones · 6d ago
Claritev, Lantern form strategic partnership for surgical cost transparency
TipRanks · 05/07 13:32
More
About LTRN
More
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
Recently
Symbol
Price
%Change

Webull offers Lantern Pharma Inc stock information, including NASDAQ: LTRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LTRN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LTRN stock methods without spending real money on the virtual paper trading platform.